Ramucirumab: A Review in Advanced Gastric Cancer

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Sarah L Greig, Gillian M Keating

Abstract

Ramucirumab (Cyramza(®)), an intravenously administered, monoclonal antibody against vascular endothelial growth factor receptor-2, is approved in the USA, EU and Japan (either as a single agent or in combination with paclitaxel) as second-line treatment in adults with advanced gastric or gastro-oesophageal junction adenocarcinoma. In two phase III trials (REGARD and RAINBOW) in this indication, overall survival and progression-free survival were significantly prolonged with ramucirumab 8 mg/kg every 2 weeks compared with placebo, and with ramucirumab 8 mg/kg every 2 weeks plus weekly paclitaxel compared with placebo plus paclitaxel. Ramucirumab had a generally acceptable tolerability profile in phase III trials; hypertension was the most common non-haematological adverse event of grade 3 or higher with ramucirumab (either alone or with paclitaxel). As the first antiangiogenic agent to provide significant survival benefit in patients with advanced gastric cancer, ramucirumab is a valuable option in the second-line treatment of advanced gastric or gastro-oesophageal junction adenocarcinoma.

References

Aug 14, 2002·World Journal of Gastroenterology : WJG·Juan RenBo-Rong Pan
May 10, 2006·Biochemical and Biophysical Research Communications·Hua-Quan MiaoZhenping Zhu
Jul 8, 2009·Nature Reviews. Clinical Oncology·Helen X Chen, Jessica N Cleck
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer L SpratlinS Gail Eckhardt
Mar 20, 2010·The Cochrane Database of Systematic Reviews·Anna Dorothea WagnerWolfgang E Fleig
Aug 17, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Atsushi OhtsuYoon-Koo Kang
Mar 14, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jung Hun KangSe Hoon Park
Oct 8, 2013·Lancet·David H Ilson
Apr 2, 2014·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·T WaddellD Arnold
Sep 10, 2014·Current Opinion in Gastroenterology·Geoffrey Y Ku, David H Ilson
Sep 23, 2014·The Lancet Oncology·Mitsuru Sasako
Oct 16, 2014·Drugs·Gillian M Keating
Oct 31, 2014·World Journal of Gastroenterology : WJG·Ferdinando De VitaMichele Orditura
Nov 19, 2014·Nature Reviews. Clinical Oncology·Florian Lordick
May 6, 2015·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Ramanjit SihotaR M Pandey

❮ Previous
Next ❯

Citations

Nov 21, 2018·Expert Opinion on Drug Safety·Lidia Rita CorsiniAntonio Russo
Jun 5, 2020·OncoTargets and Therapy·Shanshan NieHongwei Lu
Jun 21, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Y YaoF Kong
Mar 29, 2020·Therapeutic Advances in Medical Oncology·Xiang WangDiansheng Zhong
Dec 31, 2018·Molecular Therapy. Nucleic Acids·Bao T LeRakesh N Veedu
Nov 19, 2020·Naunyn-Schmiedeberg's Archives of Pharmacology·Xu LiuDian Gao

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.